Formation of Docetaxel-related Substances in the Polymer Particles During Storage and Gamma-treatment

Introduction. Docetaxel is widely used for cancer treatment. Actual issue for newly developed polymer-based Docetaxel formulations is applicability of current quality requirements. The technology of polymeric forms, including gamma-sterilization, are differ from actual Docetaxel injections technology. In this study were used PLGA-based particles with Docetaxel. The main attention was directed to studying qualitative and quantitative content of related impurities in polymeric forms during long-term storage and gamma-sterilization in comparison with pharmacopoeial requirements for Docetaxel injections.

Aim. Studying of possible patterns of Docetaxel-related impurities formation between intact and gamma-irradiated batches.

Materials and methods. Objects of study – lyophilizates of Docetaxel polymeric forms was previously obtained by the authors. Qualitative and quantitative analysis was performed by high pressure liquid chromatography.

Results and discussion. Docetaxel-related impurities was determined and evaluated in the intact and gamma-treated batches. It was cleared, that related substances in the gamma-treated batches was different in comparison with non-treated but after vary storage periods.

Conclusion. Docetaxel-loaded polymeric drugs shown proper stability during long term storage. The influence of gamma-treatment to Docetaxelrelated impurities content was found. Gamma sterilization can be promising method for novel drugs, but it needs individual study in the each case.

1. Poltavets Y. I., Zhirnik A. S., Zavarzina V. V., Semochkina Y. P., Shuvatova V. G., Krasheninnikova A. A., Aleshin S. V., Dronov D. O., Vorontsov E. A., Posypanova G. A., Balabanyan V. Y. In vitro anticancer activity of folate-modified docetaxel-loaded PLGA nanoparticles against drug-sensitive and multidrug-resistant cancer cells. Cancer Nanotechnology. 2019; 10: 2. DOI: 10.1186/s12645-019-0048-x.

2. Bushell J. A., Claybourn M., Williams H. E., Murphy D. M. An EPR and ENDOR study of γ- and β-radiation sterilization in poly (lactide-coglycolide) polymers and microspheres. J. Control. Release. 2005; 110(1): 49–57. DOI: 10.1016/j.jconrel.2005.09.009.

3. Friess W., Schlapp M. Sterilization of gentamicin containing collagen/PLGA microparticle composites. Eur. J. Pharm. Biopharm. 2006; 63(2): 176–187. DOI: 10.1016/j.ejpb.2005.11.007.

4. Sintzel M.B., Merkli Al., Tabatabay C., Gurny R. Influence of Irradiation Sterilization on Polymers Used as Drug Carriers: A Review. Drug Development and Industrial Pharmacy. 1997; 23(9): 857–878. DOI: 10.3109/03639049709148693.

5. Maksimenko O., Pavlov E., Toushov E., Molin A., Stukalov Y., Prudskova T., Feldman V., Kreuter J., Gelperina S. Radiation sterilization of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles. Int. J. Pharm. 2008; 356(1-2): 325–332.

6. Poltavets Y. I., Zavarzina V. V., Kuznetsov S. L., Krasheninnikova A. A., Dronov D. O., Gukasova N. V., Shuvatova V. G., Balabanyan V. Y. Development of docetaxel-loaded folate-modified poly(lactic-coglycolic acid) particles. J. Rep. Pharm. Sci. 2019; 8: 253–261. DOI: 10.4103/jrptps.JRPTPS_64_19.

7. Vasu D. R., Moses B. J., Vyas K., Sai Ram P., Ramachandra P., Sekhar N. M., Mohan Reddy D. N. Srinivasa Rao N. Isolation and characterization of impurities in docetaxel. J. Pharm. Biomed. Anal. 2006; 40(3): 614–622. DOI: 10.1016/j.jpba.2005.10.037.

8. Kumar D., Tomar R.S., Deolia S.K., Mitra M., Mukherjee R., Burman A.C. Isolation and characterization of degradation in docetaxel drug substance and its formulation. J. Pharm. Biomed. Anal. 2007; 43(4): 1228–1235. DOI: 10.1016/j.jpba.2006.10.015.

9. Reddy A. M., Banda N., Dagbu S. G., Rao D. V., Kocherlakota C. S., Krishnamurthy V. Evaluation of the Pharmaceutical Quality of Docetaxel Injection Using New Stability Indicating Chromatographic Methods for Assay and Impurities. Sci. Pharm. 2010; 78(2): 215–231. DOI: 10.3797/scipharm.0912-14.

10. United States Pharmacopeia USP 38–NF 33 <Docetaxel injection> P. 3180.

11. Sanzakov M. A., Ignatov D. V., Prozorovskyi V. N., Druzhilovskaia O. S., Medvedeva N. V., Ipatova O.M. Development of targeted drug delivery system: synthesis of conjugates of address fragment (RA-COOH) with ligand (R-NH2). Biomeditsinskaia Khimiia. 2014; 60(6), 713–716 (in Russ). DOI: 10.18097/pbmc20146006713.

12. European Pharmacopoeia 8.0 07/2012:2593 Docetaxel, anhydrous, P. 2090–2092.

13. European Pharmacopoeia 8.0 07/2012:2449 Docetaxel, trihydrate, P. 2092–2093.

14. Makadia H. K., Siegel S. J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011; 3(3): 1377–1397. DOI: 10.3390/polym3031377.